Lucy Day, AN2 Therapeutics, Inc. (NASDAQ: ANTX ), chief financial officer, recently sold a portion of his holdings in the company. According to a recent filing, Day sold 2,957 shares of common stock on Jan. 3, 2025, at a price of $1.341 per share, for a total of $3,965. The transaction was entered into to meet tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on January 1, 2025. The sale came as the stock traded near $1.35, with the company trading well below its 52-week high of $22.22. Capitalization currently stands at $41.2 million.
Following this sale, Day retained ownership of 32,670 shares, including 20,625 RSUs, contingent upon his continued service to the Company over the next three years. In addition, his holdings include 5,000 shares acquired through the company’s employee stock purchase plan. Investment Prof Analysis shows that the stock is currently undervalued, with a strong financial health score and strong current ratio of 9.75. For deeper insight into AN2 Therapeutics and access to comprehensive financial metrics, view the detailed Pro Research report, available exclusively to InvestingPro subscribers.
In more recent news, AN2 Therapeutics has experienced significant growth. Results of a Phase 2 trial for the company’s EBO drug candidate, which is aimed at treating refractory nontuberculous mycobacterial infections, showed no difference in culture conversion rates, which Also TD Cowen downgraded the stock from buy to hold. A decision on whether to proceed with a Phase 3 trial of EBO is expected after discussions with the FDA in the first half of 2025.
Also, AN2 Therapeutics has announced the initiation of Phase 1 and Phase 2 trials in 2025 for the treatment of Chagas disease and melioidosis, respectively. Despite these developments, TD Cowen expressed skepticism about the potential of these trials to significantly affect the company’s valuation.
Additionally, AN2 Therapeutics has received an extension to its research grant from the Bill & Melinda Gates Foundation. The funding will support the discovery of inhibitors targeting aminoacyl-tRNA synthetases, using the company’s proprietary boron chemistry platform.
Additionally, in response to the significant acquisition of its shares by BML Investment Partners, the Company has implemented a stockholder rights plan to protect against potential coercive takeover tactics. Finally, Evercore ISI maintained an ‘In Line’ rating for AN2 Therapeutics, with the company ending the quarter with cash reserves of $118 million.
This article was produced with support from AI and was reviewed by an editor. See our T&C for more information.
